US industry opposes use of specific language in new informed consent rule
This article was originally published in RAJ Devices
Proposals by the US Food and Drug Administration to amend the informed consent requirements to increase awareness about the publicly accessible clinical trials registry, ClinicalTrials.gov, has drawn concern from the medtech industry1,2.
You may also be interested in...
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.